The increased risk of endometrial cancer associated with the use of postmenopausal estrogen therapy can be diminished by the concomitant use of progestogen on a cyclic basis. Nevertheless, it is quite uncertain whether the entirety of the increased risk is eliminated, especially in long-term users of cyclic estrogen/progestogen regimens. Additionally, the impact on endometrial cancer incidence of a now-common way of taking hormones, on a combined-continuous basis, has never been evaluated. To address these questions, a population-based case-control study of endometrial cancer is proposed for women 50-60 years of age who reside in three counties of western Washington. An attempt will be made to interview eligible cases diagnosed during 1997-1999 regarding the use of hormonal medications and other exposures and characteristics that bear on the incidence of endometrial cancer. As a basis of comparison for the cases who are 50-64 years of age, interviews will be sough with 50-64 year-old female residents of these counties identified through random digit dialing. Controls 65-69 years of age will be identified through the records of the Health Care Financing Administration, and they will be interviewed as well. Potential controls who have previously had a hysterectomy will be excluded. We anticipate obtaining interviews with approximately 300 cases and an equal number of controls. Exogenous hormones offer postmenopausal women substantial benefits with regard to their cardiovascular and skeletal systems. The proposed study has the potential to obtain information that can guide their choice of hormonal regimen so as to minimize the likelihood of endometrial cancer as an adverse effect of this otherwise useful therapy.
| Prescott, Jennifer; Setiawan, Veronica W; Wentzensen, Nicolas et al. (2015) Body Mass Index Genetic Risk Score and Endometrial Cancer Risk. PLoS One 10:e0143256 |
| Felix, Ashley S; Gaudet, Mia M; La Vecchia, Carlo et al. (2015) Intrauterine devices and endometrial cancer risk: a pooled analysis of the Epidemiology of Endometrial Cancer Consortium. Int J Cancer 136:E410-22 |
| Cote, Michele L; Alhajj, Tala; Ruterbusch, Julie J et al. (2015) Risk factors for endometrial cancer in black and white women: a pooled analysis from the Epidemiology of Endometrial Cancer Consortium (E2C2). Cancer Causes Control 26:287-296 |
| Chen, Maxine M; Crous-Bou, Marta; Setiawan, Veronica W et al. (2014) Exome-wide association study of endometrial cancer in a multiethnic population. PLoS One 9:e97045 |
| Setiawan, Veronica Wendy; Schumacher, Fredrick; Prescott, Jennifer et al. (2014) Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 35:2068-73 |
| Setiawan, Veronica Wendy; Yang, Hannah P; Pike, Malcolm C et al. (2013) Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31:2607-18 |
| Phipps, Amanda I; Doherty, Jennifer A; Voigt, Lynda F et al. (2011) Long-term use of continuous-combined estrogen-progestin hormone therapy and risk of endometrial cancer. Cancer Causes Control 22:1639-46 |
| Pocobelli, Gaia; Doherty, Jennifer A; Voigt, Lynda F et al. (2011) Pregnancy history and risk of endometrial cancer. Epidemiology 22:638-45 |
| Doherty, Jennifer A; Weiss, Noel S; Fish, Sherianne et al. (2011) Polymorphisms in nucleotide excision repair genes and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 20:1873-82 |
| Setiawan, Veronica Wendy; Doherty, Jennifer A; Shu, Xiao-Ou et al. (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium. Cancer Epidemiol Biomarkers Prev 18:242-7 |
Showing the most recent 10 out of 18 publications
